Affiliation:
1. Russian Scientific Center of Roentgenoradiology
2. Рeoples’ Friendship University of Russia; Municipal Clinical Hospital Number 1 of the Moscow City Health Department
Abstract
Aim. To evaluate the antitumor efficacy of our developed drug based on cytotoxic T lymphocytes genetically modified with a chimeric antigen receptor (CAR) specific to the CA125 antigen in relation to both CA125-positive and CA125negative cell cultures.Materials and methods. We performed an in vitro study on CA125-positive human ovarian cancer cells (OVCAR-3, OVKATE) and CA125 negative cells (breast cancer MCF 7, embryonic kidney HEK293). Cytotoxic effects on tumor cells were evaluated after 0, 4, 8 and 24 hours using the 3’-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and Lactate Dehydrogenase (LDH) tests. We also studied the changes in the number of cells “in real time” when exposed to transfected lymphocytes using the RTCA iCELLIgence device (ACEA Biosciences, USA). Lymphokineactivated killer (LAK) cells were used as a specificity control.Results. The study demonstrated that anti-CA125 CAR-T lymphocytes exhibited a pronounced cytotoxic effect on OVCAR-3 and OVKATE cell cultures, exceeding the effect of LAK by 1.3 times. The cell population in the experimental samples decreased by 70 ± 4%, which exceeded the LAK effect by 9 ± 8.2%. With regard to the MCF-7 cell line, the cytotoxic effect of anti-CA125 CAR-T lymphocytes was minimal as evidenced by a 25.8% decrease in the relative number of live cells in comparison to the LAK cytotoxicity of 68%. Real-time monitoring of cell proliferation and viability proved a high specific cytotoxic effect of anti-CA125 CAR-T lymphocytes against tumor cultures expressing CA-125, while inferior to LAK in cultures not expressing CA125 (MCF-7, HEK293).Conclusions. The use of anti-CA125 CAR-T lymphocytes against CA125-positive tumor cell lines OVCAR-3 and OVKATE demonstrated a pronounced specific cytotoxic effect exceeding the cytotoxic effect of LAK, which was not achieved against CA125-negative MCF-7 and HEK293 cells.
Reference33 articles.
1. Zhang J., Li M., Feng L., et al. Laparoscopic versus laparotomic surgical treatment in apparent stage I ovarian cancer: a multi-center retrospective cohort study. World J Surg Oncol. 2024 Feb 22; 22(1): 62. https://doi.org/10.1186/s12957-024-03345-1. PMID: 38389046; PMCID: PMC10882876
2. Jokhadze N., Das A., Dizon D.S. Global cancer statistics: A healthy population relies on population health. CA Cancer J Clin. 2024 May-Jun; 74(3): 224–226. https://doi.org/10.3322/caac.21838. Epub 2024 Apr 4. PMID: 38572764
3. Kotova E.G., Papanova E.K., Adamyan L.V. Timely detection and treatment of malignant neoplasms of the reproductive organs in women as a reserve for increasing life expectancy in the Russian Federation. Russian Journal of Human Reproduction. 2023; 29(6): 6–11 (In Russian). https://doi.org/10.17116/repro2023290616
4. Osann K., Wenzel L., McKinney C., et al. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecol Oncol. 2023 Apr; 171: 151– 158. https://doi.org/10.1016/j.ygyno.2023.02.015. Epub 2023 Mar 9. PMID: 36905875; PMCID: PMC10681156.
5. Yu Y., Li X.B., Lin Y.L., et al. Effi cacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Mar 25; 24(3): 230–239. Chinese. https://doi.org/10.3760/cma.j.cn.441530-20201110-00603. PMID: 34645167